



**A Phase III Randomized, Multicenter Trial Comparing
Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-
Versus-Host Disease (GVHD) Prophylaxis After HLA-
Matched, Related Peripheral Blood Stem Cell Transplantation**

**BMT CTN PROTOCOL 0402
Version 4.0**

Core Study Participants:

City of Hope National Medical Center
Dana Farber Cancer Institute
Duke University Medical Center
Ohio State University
Stanford University Medical Center
University Hospitals of Cleveland
University of California, San Diego
University of Florida College of Medicine
University of Michigan Medical Center
University of Minnesota
University of Pennsylvania Cancer Center
University of Washington, Barnes Jewish Hospital

Non-Core Study Participants:

Baylor University Medical Center
Emory University Medical Center
Henry Ford Health System
Hospital Saint-Louis
Indiana University
Mayo Clinic
Roswell Park Cancer Institute
Texas Transplant Institute
Virginia Commonwealth University MCV Hospitals
University of Iowa Hospitals and Clinics
University of Oklahoma Medical Center
University of Pittsburgh Cancer Institute
University of Wisconsin Hospital & Clinics